ATEZOLIZUMAB for Melanoma

Inclusion criteria

• {"criterion_text":"- Patients of either sex aged ≥18 years\n- Female subjects of childbearing potential must have a negative pregnancy test result at baseline and must practice a reliable method of contraception for the total study duration plus 24 weeks after the last dose of experimental drugs.\n- Men who are sexually active with women of childbearing potential must practice a reliable method of contraception for the total study duration plus 24 weeks after the last dose of experimental drugs.\n- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form\n- Patients must have histologically or cytologically confirmed Stage IIIB/C/D resectable cutaneous melanoma. The definition of resectability can be determined by the patient's surgical oncologist and verified via discussion at Multidisciplinary Tumour Conference attended by melanoma medical and surgical oncology staff. Resectable tumours are defined as having no significant vascular, neural or bony involvement. Only cases where a complete surgical resection with tumour-free margins can safely be achieved are defined as resectable\n- All patients must have a BRAF V600E/K mutation status known\n- Patients must be medically fit enough to undergo surgery as determined by the surgical oncology team\n- Patients must have measurable disease, defined by RECIST 1.1\n- Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n- Patients must have organ and marrow function as described\n- Absence of any psychological, familiar or social condition that may affect compliance with study protocol and scheduled follow-up"}

Exclusion criteria

• {"criterion_text":"- No previous cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug\n- Prior BRAF or MEK targeted therapy; patients who have received prior interferon are eligible\n- History of retinopathy or any finding at ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular de generation\n- History of ocular/uveal/mucosal melanoma\n- Presence of any of the following risk factors for RVO: a) Uncontrolled glaucoma with intra-ocular pressures ≥ 21mmHg; b) Serum cholesterol ≥Grade 2; c) Hypertriglyceridemia ≥ Grade 2; d) Hyperglycaemia (fasting) ≥Grade 2\n- Correct QT interval > 450 msec to baseline, history of congenital long QT syndrome\n- Uncontrolled medical condition among which endocrine disorders (such as hypothyroidism, hyperthyroidism and diabetes mellitus)\n- Other severe medical or psychiatric conditions (e.g. depression) or abnormalities of laboratory tests that may increase the risk associated with study participation or the assumption of Vemurafenib, Atezolizumab and Cobimetinib, or that may interfere with the interpretation of study results, which in the judgment of the Investigator can make the patient not eligible for the study\n- Uncontrolled intercurrent illness, including but not limited to: ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, cerebrovascular accident or transient ischemic attack, pulmonary embolism, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n- History of active primary immunodeficiency\n- Receipt of live attenuated vaccine within 30 days prior to the first dose. Note: enrolled patients should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP.\n- Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, thyroid cancer (except anaplastic) or any cancer from which the patient has been disease-free for 2 years\n- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA- 4 antibody\n- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients\n- Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection\n- History of testing positive for HIV or known AIDS\n- Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.\n- Any major surgery within the last 3 weeks\n- Pregnancy and/or breast feeding or of childbearing potential and not practicing a reliable method of birth control\n- Unwillingness or inability to follow the procedures required in the protocol\n- Uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity\n- Current use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels\n- History of uncontrolled cardiovascular or interstitial lung disease and evidence or risk of retinal vein occlusion or central serous retinopathy\n- Subjects with conditions requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment"}

Primary endpoints

• {"endpoint_text":"- The primary objective is to determine the pathologic complete response (pCR) rate. (Centrally/Independently determined). Pathologic complete response, which is defined as residual cancer burden 0.","definition_or_measurement_approach":"Centrally/Independently determined. Pathologic complete response defined as residual cancer burden 0."}

Secondary endpoints

• {"endpoint_text":"- Recurrence-Free Survival (RFS) at 2-years, 3-years and at the end of the study. RFS defined as the time from randomisation to recurrence event (local or distant disease development, or death). For patients without events at the end of the study time will be censored at the date of last follow-up.\n- Overall Survival (OS) defined as the time from randomisation to death. For patients alive at the end of the study time will be censored at the date of last follow-up.\n- Pathological Overall Response rate (pORR) defined as the sum of pathologic complete responses (pCRs), near pathologic complete responses (near pCRs) and pathologic partial responses (pPRs).\n- Safety\n- To determine molecular and immunophenotypic changes in tumour and peripheral blood evaluating several biomarkers.","definition_or_measurement_approach":"RFS: time from randomisation to recurrence event (local or distant disease development, or death); censor at date of last follow-up if no event. OS: time from randomisation to death; censor at date of last follow-up if alive. pORR: sum of pCRs, near pCRs and pPRs. Safety: standard safety assessments (not further detailed in CTIS record). Biomarkers: molecular and immunophenotypic changes in tumour and peripheral blood (no further measurement details provided)."}

Italy

Earliest CTIS Part Ii Submission Date

25-07-2024

Latest Decision Or Authorization Date

03-01-2025

Processing Time Days

162

Number Of Sites

6

Number Of Participants

94

Primary sponsor

Full Name

Fondazione Melanoma Onlus

Organisation Type

Laboratory/Research/Testing facility

Country Of Registered Address

Italy